Symposia: Outcomes Research—Lymphoid Malignancies
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, Plasma Cell Disorders, health disparities research, Diversity, Equity, and Inclusion (DEI) , patient-reported outcomes, Diseases, real-world evidence, Lymphoid Malignancies, Adverse Events, survivorship
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Clinical Research, health outcomes research, Plasma Cell Disorders, health disparities research, Diversity, Equity, and Inclusion (DEI) , patient-reported outcomes, Diseases, real-world evidence, Lymphoid Malignancies, Adverse Events, survivorship
Monday, December 11, 2023: 4:30 PM-6:00 PM
Marriott Grand Ballroom 2-4
(Marriott Marquis San Diego Marina)
Moderators:
Shonali Midha, MD, BS, Dana-Farber Cancer Institute
and
Mazie Tsang, MD, UCSF
Disclosures:
Midha: Abbvie: Current holder of stock options in a privately-held company; Pfizer: Consultancy. Tsang: Poseida Therapeutics: Current holder of stock options in a privately-held company; Novartis: Consultancy.
In this session we will try to understand the balance between efficacy, safety and tolerability, and the importance of quality of life and patient-reported outcome measurement (PROM) in patients with multiple myeloma according different treatment strategies.
4:30 PM
4:45 PM
5:00 PM
5:15 PM
5:30 PM
5:45 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH